CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Fool
- Therapeutic Impact: CRISPR Therapeutics' gene-editing therapy Casgevy was approved in 2023, and despite a steep price of $2.2 million per patient, over 500 patients have begun treatment, indicating initial market acceptance; however, the high cost remains a significant barrier to broader adoption.
- Strong Financial Position: With a market cap of $5.5 billion and over $2.4 billion in liquidity, the consensus analyst price target of $80.62 is 40% above the current stock price, yet the stock has stagnated since 2022, reflecting concerns about future profitability.
- Complex Treatment Process: The Casgevy therapy requires personalized customization using patients' own blood stem cells, making the treatment process complex and time-consuming, which delays revenue recognition and pressures short-term financial performance.
- Financing and Dilution Risks: The company issued $600 million in convertible notes in March, potentially diluting the existing 96.5 million shares, which, while common in biotech financing, raises investor concerns about future profitability and share value stability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 49.440
Low
50.00
Averages
78.89
High
105.00
Current: 49.440
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline
- Therapeutic Impact: CRISPR Therapeutics' gene-editing therapy Casgevy was approved in 2023, and despite a steep price of $2.2 million per patient, over 500 patients have begun treatment, indicating initial market acceptance; however, the high cost remains a significant barrier to broader adoption.
- Strong Financial Position: With a market cap of $5.5 billion and over $2.4 billion in liquidity, the consensus analyst price target of $80.62 is 40% above the current stock price, yet the stock has stagnated since 2022, reflecting concerns about future profitability.
- Complex Treatment Process: The Casgevy therapy requires personalized customization using patients' own blood stem cells, making the treatment process complex and time-consuming, which delays revenue recognition and pressures short-term financial performance.
- Financing and Dilution Risks: The company issued $600 million in convertible notes in March, potentially diluting the existing 96.5 million shares, which, while common in biotech financing, raises investor concerns about future profitability and share value stability.
See More
CRISPR Therapeutics Shows Promising Future Potential
- Commercialization Progress: CRISPR Therapeutics' gene-editing treatment Casgevy, co-developed with Vertex Pharmaceuticals, received FDA approval in late 2023, marking the company's first successful commercialization, although only 64 patients received treatment in 2025, generating $4.1 million in sales.
- Revenue Growth Expectations: Analysts forecast the company's revenue to reach $43.9 million this fiscal year and $151.6 million next year, indicating significant potential in the gene therapy market; despite one-time treatments not generating recurring revenue, there is a vast eligible patient pool estimated at 60,000 in the U.S. and other approved countries.
- Strong R&D Pipeline: CRISPR has five other therapies in various clinical trial stages, four of which are wholly owned by the company, meaning substantial financial upside if one or two succeed, further solidifying its market position.
- Investment Opportunity: Although CRISPR's market cap stands at $5.4 billion with a price-to-earnings ratio of about 35 based on next year's revenue estimates, the strong R&D pipeline and the success of Casgevy suggest a potential 437% upside, making the stock an attractive option for investors.
See More
CRISPR's Casgevy Establishes Leadership in Gene-Editing Therapies
- Market Leadership: CRISPR Therapeutics' Casgevy gene-editing therapy has received FDA approval, establishing the company's leadership in treating sickle cell disease and transfusion-dependent beta thalassemia, which is expected to drive commercial growth over the next decade.
- Sales Growth Potential: Although only 64 patients received Casgevy infusions in 2025, CRISPR anticipates revenue reaching $43.9 million this fiscal year and growing to $151.6 million next year, indicating strong market demand and potential revenue growth.
- Robust R&D Pipeline: CRISPR has five therapies at various stages of clinical trials, four of which are wholly owned by the company, and successful market entry of even one or two could significantly enhance financial performance and competitive positioning.
- Investor Confidence: With 58% of Wall Street analysts rating CRISPR as a buy and price targets suggesting up to 437% upside, the current market cap of $5.4 billion is viewed as a potential investment opportunity for the next decade.
See More
Eli Lilly's Gene Editing Drug Shows Significant Progress
- Weight Loss Market Growth: Eli Lilly's weight-loss drug Zepbound has become a best-seller, and the recently approved oral weight-loss pill Foundayo is also performing well, showcasing the company's strong competitive position in the rapidly growing weight-loss drug market.
- Gene Editing Potential: Eli Lilly's clinical trial results for VERVE-102 indicate that a one-time infusion can significantly lower LDL cholesterol with durable effects, potentially offering a revolutionary treatment option for high-risk cardiovascular patients and further solidifying its position in the gene editing space.
- Market Competition Landscape: While CRISPR Therapeutics' CTX310 also aims to reduce LDL and triglycerides, both target different patient populations and have distinct mechanisms, suggesting that the gene editing market could accommodate multiple winners, with Eli Lilly's entry posing a threat to smaller gene editing firms.
- Investment Choice Analysis: As an established pharmaceutical company, Eli Lilly offers stable revenue and profits, with its exploration in gene editing providing a relatively safe option for investors, whereas CRISPR Therapeutics presents a higher-risk, higher-reward investment opportunity suitable for those with a greater risk tolerance.
See More
Eli Lilly Reports Positive Results for Gene Editing Candidate
- Clinical Trial Results: Eli Lilly's recent announcement regarding VERVE-102 shows that the gene editing candidate significantly lowers LDL cholesterol, potentially offering a one-time treatment option for high-risk cardiovascular patients, which could revolutionize treatment approaches.
- Market Competition: Eli Lilly is competing with CRISPR Therapeutics in the gene editing space, targeting different patient populations, yet both aim at the vast market of 40 million Americans with elevated LDL or triglycerides, highlighting the immense potential in gene editing.
- Robust Pipeline: In addition to VERVE-102, Eli Lilly's success in the weight-loss drug market with products like Zepbound and Foundayo provides financial backing for its gene editing research, further solidifying its leadership position in the pharmaceutical industry.
- Strategic Vision: Eli Lilly's exploration in gene editing not only complements its existing market but may also open new revenue streams for future growth, enhancing its competitiveness in the rapidly evolving biotechnology sector.
See More
FDA Issues Draft Guidance to Accelerate Gene Therapy Development
- Draft Guidance Release: The FDA has issued a draft guidance aimed at accelerating the R&D process for gene and cell therapies by leveraging existing scientific and regulatory knowledge, which is expected to significantly enhance the approval efficiency of therapeutic products.
- Streamlined Regulatory Submissions: The guidance will clarify how sponsors can utilize publicly available information and established platform knowledge, including chemistry, manufacturing, and controls (CMC) data, to simplify regulatory submissions for human gene therapy products, thereby reducing compliance costs for companies.
- Early Engagement Recommendations: The FDA encourages companies to engage with it before submitting an IND application, including participating in Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings, to ensure their development plans align with regulatory expectations, thus increasing their chances of success.
- Significant Industry Impact: The release of this draft guidance is likely to have a positive impact on leading gene and cell therapy biopharma companies, such as CRISPR Therapeutics and Intellia Therapeutics, potentially accelerating their product launch timelines and fostering overall industry growth.
See More
CRISPR Therapeutics Faces Stagnant Stock Despite Promising Pipeline
- Therapeutic Impact: CRISPR Therapeutics' gene-editing therapy Casgevy was approved in 2023, and despite a steep price of $2.2 million per patient, over 500 patients have begun treatment, indicating initial market acceptance; however, the high cost remains a significant barrier to broader adoption.
- Strong Financial Position: With a market cap of $5.5 billion and over $2.4 billion in liquidity, the consensus analyst price target of $80.62 is 40% above the current stock price, yet the stock has stagnated since 2022, reflecting concerns about future profitability.
- Complex Treatment Process: The Casgevy therapy requires personalized customization using patients' own blood stem cells, making the treatment process complex and time-consuming, which delays revenue recognition and pressures short-term financial performance.
- Financing and Dilution Risks: The company issued $600 million in convertible notes in March, potentially diluting the existing 96.5 million shares, which, while common in biotech financing, raises investor concerns about future profitability and share value stability.
See More
CRISPR Therapeutics Shows Promising Future Potential
- Commercialization Progress: CRISPR Therapeutics' gene-editing treatment Casgevy, co-developed with Vertex Pharmaceuticals, received FDA approval in late 2023, marking the company's first successful commercialization, although only 64 patients received treatment in 2025, generating $4.1 million in sales.
- Revenue Growth Expectations: Analysts forecast the company's revenue to reach $43.9 million this fiscal year and $151.6 million next year, indicating significant potential in the gene therapy market; despite one-time treatments not generating recurring revenue, there is a vast eligible patient pool estimated at 60,000 in the U.S. and other approved countries.
- Strong R&D Pipeline: CRISPR has five other therapies in various clinical trial stages, four of which are wholly owned by the company, meaning substantial financial upside if one or two succeed, further solidifying its market position.
- Investment Opportunity: Although CRISPR's market cap stands at $5.4 billion with a price-to-earnings ratio of about 35 based on next year's revenue estimates, the strong R&D pipeline and the success of Casgevy suggest a potential 437% upside, making the stock an attractive option for investors.
See More
CRISPR's Casgevy Establishes Leadership in Gene-Editing Therapies
- Market Leadership: CRISPR Therapeutics' Casgevy gene-editing therapy has received FDA approval, establishing the company's leadership in treating sickle cell disease and transfusion-dependent beta thalassemia, which is expected to drive commercial growth over the next decade.
- Sales Growth Potential: Although only 64 patients received Casgevy infusions in 2025, CRISPR anticipates revenue reaching $43.9 million this fiscal year and growing to $151.6 million next year, indicating strong market demand and potential revenue growth.
- Robust R&D Pipeline: CRISPR has five therapies at various stages of clinical trials, four of which are wholly owned by the company, and successful market entry of even one or two could significantly enhance financial performance and competitive positioning.
- Investor Confidence: With 58% of Wall Street analysts rating CRISPR as a buy and price targets suggesting up to 437% upside, the current market cap of $5.4 billion is viewed as a potential investment opportunity for the next decade.
See More
Eli Lilly's Gene Editing Drug Shows Significant Progress
- Weight Loss Market Growth: Eli Lilly's weight-loss drug Zepbound has become a best-seller, and the recently approved oral weight-loss pill Foundayo is also performing well, showcasing the company's strong competitive position in the rapidly growing weight-loss drug market.
- Gene Editing Potential: Eli Lilly's clinical trial results for VERVE-102 indicate that a one-time infusion can significantly lower LDL cholesterol with durable effects, potentially offering a revolutionary treatment option for high-risk cardiovascular patients and further solidifying its position in the gene editing space.
- Market Competition Landscape: While CRISPR Therapeutics' CTX310 also aims to reduce LDL and triglycerides, both target different patient populations and have distinct mechanisms, suggesting that the gene editing market could accommodate multiple winners, with Eli Lilly's entry posing a threat to smaller gene editing firms.
- Investment Choice Analysis: As an established pharmaceutical company, Eli Lilly offers stable revenue and profits, with its exploration in gene editing providing a relatively safe option for investors, whereas CRISPR Therapeutics presents a higher-risk, higher-reward investment opportunity suitable for those with a greater risk tolerance.
See More
Eli Lilly Reports Positive Results for Gene Editing Candidate
- Clinical Trial Results: Eli Lilly's recent announcement regarding VERVE-102 shows that the gene editing candidate significantly lowers LDL cholesterol, potentially offering a one-time treatment option for high-risk cardiovascular patients, which could revolutionize treatment approaches.
- Market Competition: Eli Lilly is competing with CRISPR Therapeutics in the gene editing space, targeting different patient populations, yet both aim at the vast market of 40 million Americans with elevated LDL or triglycerides, highlighting the immense potential in gene editing.
- Robust Pipeline: In addition to VERVE-102, Eli Lilly's success in the weight-loss drug market with products like Zepbound and Foundayo provides financial backing for its gene editing research, further solidifying its leadership position in the pharmaceutical industry.
- Strategic Vision: Eli Lilly's exploration in gene editing not only complements its existing market but may also open new revenue streams for future growth, enhancing its competitiveness in the rapidly evolving biotechnology sector.
See More
FDA Issues Draft Guidance to Accelerate Gene Therapy Development
- Draft Guidance Release: The FDA has issued a draft guidance aimed at accelerating the R&D process for gene and cell therapies by leveraging existing scientific and regulatory knowledge, which is expected to significantly enhance the approval efficiency of therapeutic products.
- Streamlined Regulatory Submissions: The guidance will clarify how sponsors can utilize publicly available information and established platform knowledge, including chemistry, manufacturing, and controls (CMC) data, to simplify regulatory submissions for human gene therapy products, thereby reducing compliance costs for companies.
- Early Engagement Recommendations: The FDA encourages companies to engage with it before submitting an IND application, including participating in Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products (INTERACT) and pre-IND meetings, to ensure their development plans align with regulatory expectations, thus increasing their chances of success.
- Significant Industry Impact: The release of this draft guidance is likely to have a positive impact on leading gene and cell therapy biopharma companies, such as CRISPR Therapeutics and Intellia Therapeutics, potentially accelerating their product launch timelines and fostering overall industry growth.
See More
